Inhibitory refluksu - Nowa metoda leczenia farmakologicznego choroby refluksowej przełyku

Grazyna Jurkowska; Agnieszka Świdnicka-Siergiejko; Andrzej Da̧browski

doi:10.5114/pg.2012.28645

Inhibitory refluksu - Nowa metoda leczenia farmakologicznego choroby refluksowej przełyku

Translated title of the contribution: Reflux inhibitors - New therapy of gastroesophageal reflux disease

Grazyna Jurkowska, Agnieszka Świdnicka-Siergiejko, Andrzej Da̧browski

Cancer Biology

Research output: Contribution to journal › Review article › peer-review

Abstract

The most relevant target for the treatment of refractory gastroesophageal reflux disease (GERD) is controlling the occurrence of transient lower esophageal relaxations (TLESR), which represent the main mechanism of all types of reflux. Drugs in development that have this mechanism of action are now described as reflux inhibitors. The most promising among these appear to be mGluR5 agonists and GABAB receptor agonists, which reduce the number of reflux episodes and improve reflux-related symptoms. Reflux inhibitors appear to have a potential role in the management of refractory GERD as add-on therapy in combination with PPI. Future studies will establish the safety and tolerability of the new anti-reflux therapy.

Translated title of the contribution	Reflux inhibitors - New therapy of gastroesophageal reflux disease
Original language	Polish
Pages (from-to)	57-62
Number of pages	6
Journal	Przeglad Gastroenterologiczny
Volume	7
Issue number	2
DOIs	https://doi.org/10.5114/pg.2012.28645
State	Published - 2012

Keywords

GABA receptors
Gastroesophageal reflux
Glutamate receptors
Transient lower esophageal sphincter relaxation

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.5114/pg.2012.28645

Cite this

@article{89d7de1c83be422c96e31fe0c6055687,

title = "Inhibitory refluksu - Nowa metoda leczenia farmakologicznego choroby refluksowej prze{\l}yku",

abstract = "The most relevant target for the treatment of refractory gastroesophageal reflux disease (GERD) is controlling the occurrence of transient lower esophageal relaxations (TLESR), which represent the main mechanism of all types of reflux. Drugs in development that have this mechanism of action are now described as reflux inhibitors. The most promising among these appear to be mGluR5 agonists and GABAB receptor agonists, which reduce the number of reflux episodes and improve reflux-related symptoms. Reflux inhibitors appear to have a potential role in the management of refractory GERD as add-on therapy in combination with PPI. Future studies will establish the safety and tolerability of the new anti-reflux therapy.",

keywords = "GABA receptors, Gastroesophageal reflux, Glutamate receptors, Transient lower esophageal sphincter relaxation",

author = "Grazyna Jurkowska and Agnieszka {\'S}widnicka-Siergiejko and Andrzej D{\c a}browski",

year = "2012",

doi = "10.5114/pg.2012.28645",

language = "Polish",

volume = "7",

pages = "57--62",

journal = "Przeglad Gastroenterologiczny",

issn = "1895-5770",

publisher = "Termedia Publishing House Ltd.",

number = "2",

}

TY - JOUR

T1 - Inhibitory refluksu - Nowa metoda leczenia farmakologicznego choroby refluksowej przełyku

AU - Jurkowska, Grazyna

AU - Świdnicka-Siergiejko, Agnieszka

AU - Da̧browski, Andrzej

PY - 2012

Y1 - 2012

N2 - The most relevant target for the treatment of refractory gastroesophageal reflux disease (GERD) is controlling the occurrence of transient lower esophageal relaxations (TLESR), which represent the main mechanism of all types of reflux. Drugs in development that have this mechanism of action are now described as reflux inhibitors. The most promising among these appear to be mGluR5 agonists and GABAB receptor agonists, which reduce the number of reflux episodes and improve reflux-related symptoms. Reflux inhibitors appear to have a potential role in the management of refractory GERD as add-on therapy in combination with PPI. Future studies will establish the safety and tolerability of the new anti-reflux therapy.

AB - The most relevant target for the treatment of refractory gastroesophageal reflux disease (GERD) is controlling the occurrence of transient lower esophageal relaxations (TLESR), which represent the main mechanism of all types of reflux. Drugs in development that have this mechanism of action are now described as reflux inhibitors. The most promising among these appear to be mGluR5 agonists and GABAB receptor agonists, which reduce the number of reflux episodes and improve reflux-related symptoms. Reflux inhibitors appear to have a potential role in the management of refractory GERD as add-on therapy in combination with PPI. Future studies will establish the safety and tolerability of the new anti-reflux therapy.

KW - GABA receptors

KW - Gastroesophageal reflux

KW - Glutamate receptors

KW - Transient lower esophageal sphincter relaxation

UR - http://www.scopus.com/inward/record.url?scp=84861731571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861731571&partnerID=8YFLogxK

U2 - 10.5114/pg.2012.28645

DO - 10.5114/pg.2012.28645

M3 - Review article

AN - SCOPUS:84861731571

SN - 1895-5770

VL - 7

SP - 57

EP - 62

JO - Przeglad Gastroenterologiczny

JF - Przeglad Gastroenterologiczny

IS - 2

ER -

Inhibitory refluksu - Nowa metoda leczenia farmakologicznego choroby refluksowej przełyku

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this